top
Please input keywords
포스터 다운로드
ASCO 2022: A first-in-human phase I dose escalation of YH001 (CTLA-4 mAb) in combination with PD-1 mAb in patients with advanced solid tumors
YH001 is a humanized anti-hCTLA-4 IgG1 mAb that relieves CTLA-4-mediated immunosuppression, and thereby enhances the T-cell-mediated antitumor immune response. Pre-clinical data have shown potent anti-cancer activity when combined with anti-PD-1 mAb.

YH001 was well tolerated up to 4 mg/kg dose levels when combined with toripalimab and has shown encouraging antitumor activity in patients with advanced solid tumors. Clinical trial information: NCT04357756.
*Name
*Email
*Telephone
*Company
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*City